Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.16.2 (PCP)
 3,761 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A battery of 12 neuropsychological tests were administered on two occasions to 15 chronic PCP users who reduced or eliminated use of PCP over a 4-week period. A comparison sample of 15 non-PCP drug users who did not differ in age, sex, education, and ethnic composition also were tested at the two time periods. Impairment, initially higher for PCP users, decreased significantly after reduction in use of PCP. A nonsignificant increase in impairment was found for non-PCP drug users. Analysis of each variable revealed that substantial improvement occurred on the acquisition, recall, and delayed recall scores of the Randt Memory Test. Improvement also was noted for some individuals on Trails B and Digit Symbol tests.
 ...
PMID:Recovery of neuropsychological functions during reduction in use of phencyclidine. 202 71

We studied the effects of Phencyclidine (PCP, Angel Dust) on the developing chick embryo brain. In Group-1, the eggs were injected with PCP on the 7th day of incubation and the embryo brains were studied on the 10th day. In Group-2, eggs were injected twice; first on the 7th day and then on the 10th day of incubation. Group-2 brains were then studied on the 16th day of incubation. PCP significantly depressed the development of embryo brains. Cerebral hemisphere weight, total protein and total DNA were significantly lower on day 10 of incubation in Group-1. Similar results were observed in Group-2. Concomitantly, the concentration of brain serotonin at day 10 was also significantly reduced when PCP was injected into the eggs on the 7th day of incubation. Since serotonin has been reported to influence development of the chick embryo brain, the present finding of the effect of PCP on brain development might be a secondary phenomenon. The possible implications of the effects of PCP on human brain development are also discussed.
 ...
PMID:Toxic effects of phencyclidine on developing chick embryo brain. 362 65

[3H]Phencyclidine (PCP, Angel Dust) receptors have been characterized using a rat brain binding section technique. [3H]PCP labels a single class of site in rat brain (KD = 46 nM; Bmax = 10.5 fmol/slice). Ligand selectivity pattern strongly suggests that [3H]PCP binds to sites relevant for its pharmacological actions. Chronic PCP treatment (10 mg/kg/day for 14 days) decreases the number of sites (Bmax) for [3H]PCP and [3H]spiperone binding but not for [3H]dihydromorphine. These modifications could be related to the development of tolerance and dependence to PCP. Visualization of [3H]PCP binding sites shows high densities of receptors in cortical areas and hippocampus. Lower densities are observed in caudate-putamen, nucleus accumbens, and amygdala. Negligible quantities of receptors are seen in brain stem and over white matter. The presence of specific [3H]PCP binding sites in rat brain suggests the possible existence of an endogenous ligand for this unique receptor.
 ...
PMID:Properties of the phencyclidine (PCP) receptors. 632 Feb 96

The National Institute of Standards and Technology (formerly the National Bureau of Standards), in cooperation with the College of American Pathologists (CAP), has certified the concentrations of phencyclidine (PCP) in two new reference materials (RMs). One of these materials is Standard Reference Material (SRM) 1511, Multidrugs of Abuse in Freeze-dried Urine, and the other material is a CAP PCP RM. In order to minimize the possibility of undetected bias, two independent analytical methods, employing gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry, were used to certify PCP in these materials. Results from the two methods were in good agreement and were statistically combined to yield certified values of 23.8 ng/mL for PCP in SRM 1511 and 11.9, 23.4, and 49.5 ng/mL for three levels of PCP in the CAP RM. A round-robin study of SRM 1511 among five military laboratories demonstrated the suitability of the SRM for its intended purpose.
 ...
PMID:Certification of phencyclidine in lyophilized human urine reference materials. 883 50

Phencyclidine hydrochloride (PCP) also known as Angel Dust is a very potent psychotomimetic drug of abuse. Besides its central nervous system (CNS) effects PCP produces a number of adverse effects in a variety of tissues including the cardiovascular system. Since PCP is known to alter the cellular calcium homeostasis the present studies were initiated to determine the changes in cardiac Ca2+ ATPase activity in rats treated with PCP. For in vitro studies the cardiac sarcoplasmic reticulum (SR) fractions prepared from normal rats were incubated with 25, 50 and 100 microM PCP and the enzyme activities were estimated. Whereas, for in vivo studies the cardiac SR fractions prepared from rats treated with PCP (10 mg/kg body wt. single dose, intra-peritoneally (i.p.)) and sacrificed at different time intervals were used. PCP reduced the Ca2+ ATPase activity significantly both in vitro and in vivo. A 50% inhibition of the enzyme activity was obtained with 100 microM PCP in vitro. A significant reduction of SR Ca2+ ATPase was also evident as early as 1 h after treatment of rats with PCP. The reduction of Ca2+ ATPase activity in SR was irreversible even at 12 h after treatment. The in vitro kinetic studies revealed that PCP was found to be a competitive inhibitor of Ca2+ ATPase with respect to the substrate, ATP, and non-competitive with respect to Ca2+ activation. These results indicate that PCP alters the myocardial Ca2+ homeostasis by inhibiting the Ca2+ ATPase in cardiac SR in rats. Inhibition of SR Ca2+ ATPase may result in the impairment of contraction and relaxation coupling processes in the myocardium.
 ...
PMID:Phencyclidine block of Ca2+ ATPase in rat heart sarcoplasmic reticulum. 977 88